Skip to main content
Signal8

Petros Pharmaceuticals, Inc. (PTPI)

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc.

OTC:PTPIHealthcare
+3.00%$0.0031
Mkt Cap$131K
EV-
Float42.28M
O/S42.37M
VOL56K sh
$ Vol$163
RVOL0.40×
Inst Own-
SI0.2%
Net Cash/Sh-
Dilution
Petros Pharmaceuticals, Inc. logoOTC:PTPI$0.0031+3.00%

Petros Pharmaceuticals, Inc. (PTPI) dilution facts from SEC filings

Snapshot as of Jun 30, 2026, built from 31 SEC filings.

Shelf registration
S-3 filed May 3, 2024, effective May 20, 2024
Source: 10-K filed Apr 15, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
3 warrant series recorded as outstanding
Most recent offering
None recorded in the filings reviewed

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro